Roundup of the latest antibody biotech deals (June 2026)
A lot this month!! Hi, I monitor news about antibodies specifically in the biotech industry. These are the news that I have seen that are of interest from June 2026.
🤝 Incyte to acquire Vega Therapeutics, expanding its hematology portfolio into bleeding disorders in up to $2B deal. VGA039, a novel investigational mAb that targets Protein S in Phase 3 development for von Willebrand disease (VWD). https://investor.incyte.com/news-releases/news-release-details/incyte-acquire-vega-therapeutics-wholly-owned-subsidiary-star
🤝 AbbVie to acquire Apogee Therapeutics in $10.9B deal, adding zumilokibart to their pipeline. The late-stage, half-life extended mAb targeting IL-13 is in development for patients with atopic dermatitis. https://news.abbvie.com/2026-06-22-AbbVie-to-Acquire-Apogee-Therapeutics,-Deepening-Immunology-Portfolio
🤝 J&J to acquire Firefly Bio in $1B deal, expanding oncology pipeline with novel degrader antibody conjugate (DAC) platform for KRAS-driven tumors. https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-to-Acquire-Firefly-Bio-Inc--to-Expand-Oncology-Pipeline-with-Novel-Degrader-Antibody-Conjugate-Platform/default.aspx
🤝 Merck KGaA to acquire Bio-Techne for $11.3B, gaining portfolio of cytokines, growth factors, antibodies, and immunoassay kits. https://www.emdgroup.com/en/news/agreement-to-acquire-bio-techne-25-06-2026.html
🤖 Protillion Biosciences announces AI protein drug discovery collaboration with Merck in $510M deal. https://www.protillion.com/protillion-merck-collaboration
💸 Ona Therapeutics raises $86.6M Series B to advance ADCs targeting aggressive and refractory cancer indications into clinical development. https://ona-therapeutics.com/press-release/ona-therapeutics-raises-86m/
🤝 Rallybio Corporation and Avenzo Therapeutics announce merger to advance next-generation oncology therapies including ADCs, and $215M concurrent private placement. https://avenzotx.com/press-releases/rallybio-corporation-and-avenzo-therapeutics-announce-merger-agreement-to-advance-next-generation-oncology-therapies-and-215-million-concurrent-private-placement/
💸 Tavo Biotherapeutics announces $17M Series A to advance novel therapies in glaucoma and retinal disease, including a bispecific targeting both VEGF and an undisclosed protein. https://tavobio.com/#news
🥷 Ethyreal Bio emerges from stealth with $101M Series A to advance ETHY-001, an anti-TSHR antibody for thyroid eye disease and Graves’ disease. https://www.ethyrealbio.com/ethyreal-bio-emerges-from-stealth-with-101-million-in-financing-to-advance-ethy-001-a-potentially-best-in-class-anti-tshr-antibody-for-thyroid-eye-disease-and-graves-disease/
💸 Triveni Bio raises $65M Series C to support TRIV-573, a half-life extended bispecific antibody targeting KLK5/7 and IL-13, into clinical studies. https://triveni.bio/triveni-bio-raises-65-million-series-c-financing-to-expand-scope-of-first-in-class-bispecific-triv-573-clinical-studies-and-drive-next-stage-company-growth/
🔬 Jazz Pharmaceuticals and AbCellera to collaborate on next-generation T-cell engaging multispecific antibodies in potential $876M deal. https://investors.abcellera.com/news/news-releases/2026/Jazz-Pharmaceuticals-and-AbCellera-Announce-Collaboration-to-Discover-Next-Generation-T-cell-Engaging-Multispecific-Antibodies/default.aspx
💸 Memento Medicines launches with $93M Series A to advance Tie2 Agonist and VEGF inhibitor bispecific antibody therapy for retinal diseases. https://www.globenewswire.com/news-release/2026/06/18/3314508/0/en/memento-medicines-launches-with-93-million-series-a-financing-to-advance-tie2-agonist-and-vegf-inhibitor-bispecific-antibody-therapy-for-retinal-diseases.html
💸 Vedana Therapeutics launches with $46M Series A to advance next-generation migraine therapies: long-acting subcutaneously dosed monoclonal antibodies targeting PACAP. https://www.businesswire.com/news/home/20260617177215/en/Vedana-Therapeutics-Launches-With-%2446-Million-Series-A-Financing-to-Advance-Next-Generation-Migraine-Therapies
💸 Ollin Biosciences gets $330M Series B to advance phase 3 development of OLN324, a VEGF/Ang2 bispecific. https://ollin.bio/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026/
💸 RQ Bio announces $115M Series A to advance long-acting antibody RQB01 for full season influenza prevention. https://www.rqbiotechnology.com/news/rq-bio-announces-dollar115-million-pound855-million-series-a-financing-to-advance-long-acting-antibody-programme-rqb01-for-full-season-influenza-prevention
💸 MultiValent Biotherapies launches with $27M Series A to advance development of bivalent peptide-like drug conjugate for prostate cancer. https://www.globenewswire.com/news-release/2026/06/16/3312516/0/en/multivalent-biotherapies-launches-with-27-million-series-a-financing-to-advance-development-of-targeted-prostate-cancer-drug-conjugate.html
🤖 Chai Discovery announces license agreement with Pfizer for drug discovery with AI with Chai-3 model. https://www.businesswire.com/news/home/20260602498831/en/Chai-Discovery-Announces-License-Agreement-with-Pfizer-to-Accelerate-Drug-Discovery-with-AI
🔬 CytomX and Regeneron expand research collaboration for conditional bispecific therapeutics for the treatment of cancer, to a potential $4B total. https://ir.cytomx.com/news-releases/news-release-details/cytomx-announces-expansion-strategic-research-collaboration
🔬 BioArctic and Lilly sign research and collaboration agreement, for platform with the potential to actively transport antibodies across the blood-brain barrier, in up to $800M deal. https://www.bioarctic.com/en/bioarctic-and-lilly-sign-research-and-collaboration-agreement-combining-lilly-compound-with-bioarctics-braintransporter-technology/
💵 Antengene announces license agreement with K2 Therapeutics for two assets, including ATG-106, a preclinical CDH6 x CD3 bispecific TCE, in $1.96B deal. https://www.antengene.com/newsinfo/477
💸 Bionyra Pharma launches with $165M Series A to advance clinical stage pipeline of half-life extended mono and multispecific antibodies for immune-mediated inflammatory diseases. https://bionyra.com/bionyra-pharma-launches-with-165-million-oversubscribed-series-a-to-advance-clinical-stage-pipeline-of-next-generation-biologics-for-immune-mediated-inflammatory-diseases/
💸 Oblenio Bio gets $62M Series B to advance tri-specific T-cell engager LBL‑051 for autoimmune diseases into clinical development. https://www.obleniobio.com/oblenio-closes-62million-seriesb-to-advance-tri-specific-t-cell-engager-for-autoimmune-diseases
💵 TrueLab Biopharmaceutical announces license agreement with Bionyra Pharma for 2 monoclonal and bispecific antibodies for immune-mediated inflammatory diseases valued up to $985M. https://www.prnewswire.com/news-releases/truelab-biopharmaceutical-announces-license-agreement-with-bionyra-pharma-for-two-next-generation-monoclonal-and-bispecific-antibodies-for-immune-mediated-inflammatory-diseases-valued-up-to-985-million-302804996.html
🤝 Standard BioTools and Treeline Biosciences to merge into Treeline Biosciences, advancing a pipeline including targeted therapy antibody-drug conjugates. https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-and-treeline-biosciences-announce-merger
💵 METiS TechBio and Boulevard Bio enter license agreement for trispecific T-cell engager in $1.6B deal. The antibody was discovered via METiS’s AI-driven platform. https://www.metistechbio.com/en/qyxw/245.html